Most atropine currently prescribed for myopia control is compounded. How could this influence consistency of treatment and research results? What could current research lead to in future prescribing? Read more here.
As there are systemic side effects of atropine eye drops, they could be contraindicated in young patients with some conditions, syndromes, and when taking specific systemic medications. Medication safety is also discussed.
Atropine has been the apparent hero of myopia management since the 2006 & more recently, low dose (0.01%) atropine has become the new hero. This article describes how lower concentrations work to balance efficacy and side effects, and which should we select now.
Atropine for the treatment of childhood myopia has in recent times been more extensively researched through the ATOM trials with the latest update released on August 11,2015. The first paper in a series of three so far was published in 2006.